These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15239486)

  • 21. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
    Arca M
    Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What does the future hold for diabetic dyslipidaemia?
    Crespin SR
    Acta Diabetol; 2001; 38 Suppl 1():S21-6. PubMed ID: 11829450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
    Sever PS; Poulter NR; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes G; Mehlsen J; Nieminen MS; O'Brien ET; Ostergren J;
    Eur Heart J; 2008 Feb; 29(4):499-508. PubMed ID: 18175773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Statins (HMG-CoA reductase inhibitors)].
    Gotoda T
    Nihon Rinsho; 2006 Nov; 64(11):2113-8. PubMed ID: 17087305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aggressive lipid-lowering therapy: a clinical imperative.
    Pedersen TR
    Eur Heart J; 1998 Oct; 19 Suppl M():M15-21. PubMed ID: 9821012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns and effectiveness of lipid-lowering therapies in a managed care environment.
    Meyer JW; Schultz JS; O'Donnell JC; Patel PA; Sasane RM
    Value Health; 2005; 8(5):601-12. PubMed ID: 16176498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?
    Jones PH
    Drugs; 2000 May; 59(5):1127-35. PubMed ID: 10852644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
    Hunninghake DB
    Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients.
    Nambi V; Ballantyne CM
    Curr Atheroscler Rep; 2004 Sep; 6(5):353-8. PubMed ID: 15296701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can we afford to treat hyperlipidaemia as we should? Strategies for rational treatment.
    Durrington PN
    Atherosclerosis; 1998 Sep; 139 Suppl 1():S1-5. PubMed ID: 9811152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The power of statins: aggressive lipid lowering.
    Stein EA
    Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III25-31. PubMed ID: 12708636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trials of lipid-lowering therapy in secondary prevention of coronary heart disease.
    Olsson AG; Pedersen T; Bergdahl B
    Curr Opin Lipidol; 1995 Dec; 6(6):369-73. PubMed ID: 8750250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
    Després JP
    Am J Cardiol; 2001 Dec; 88(12A):30N-36N. PubMed ID: 11788128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ALLHAT-LLT and ASCOT-LLA trials: are the discrepancies more apparent than real?
    Hennekens CH
    Curr Atheroscler Rep; 2004 Jan; 6(1):9-11. PubMed ID: 14662102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy to reduce risk of coronary heart disease.
    Rader DJ
    Clin Cardiol; 2003 Jan; 26(1):2-8. PubMed ID: 12539806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns.
    Ruof J; Klein G; März W; Wollschläger H; Neiss A; Wehling M
    Prev Med; 2002 Jul; 35(1):48-53. PubMed ID: 12079440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Lancet; 2003 Apr; 361(9364):1149-58. PubMed ID: 12686036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.